Table 1.
Sample distribution according to the demographic and clinical variables of individuals with cancer
| Variable | Category | Frequency (%) N = 98 |
|---|---|---|
| Gender | Male | 53 (54.1) |
| Female | 45 (45.9) | |
| Age (years) | Variation | 41–88 |
| Median | 58.6 | |
| Mean (Standard Deviation) | 65.45 (10.2) | |
| Age range (years) | ≤65 | 52 (53.1) |
| >65 | 46 (46.9) | |
| Location | Proximal | 30 (30.6) |
| Distal | 68 (69.4) | |
| Topography | Colon | 82 (83.7) |
| Upper rectal | 16 (16.3) | |
| Follow-up time (months) | Variation (months) | 1.7–188.7 |
| Median | 58.6 | |
| Mean (Standard Deviation) | 70.15 (42.3) | |
| Status | Living without disease | 78 (79.5) |
| Living with disease | 2 (2.04) | |
| Death from other causes | 3 (3.06) | |
| Death from disease | 15 (15.3) | |
| Recurrence | No recurrence | 77 (78.5) |
| Local | 1 (1.02) | |
| Liver | 13 (13.2) | |
| Lung | 4 (4.08) | |
| Peritoneum | 3 (3.0) | |
| T Stage | T1/T2 | 48 (48.9) |
| T3/T4 | 50 (51.1) | |
| N Stage | N0 | 58 (59.2) |
| N+ | 40 (40.8) | |
| Overall TNM stage | S I | 39 (39.8) |
| S II | 18 (18.4) | |
| S III | 27 (27.6) | |
| S IV | 14 (14.3) | |
| Histological grade | Well differentiated (G1) | 08 (8.2) |
| Moderately differentiated (G2) | 84 (85.7) | |
| Poorly differentiated (G3) | 06 (6.3) | |
| Blood embolization | No | 95 (96.9) |
| Yes | 3 (3.1) | |
| Perineural invasion | No | 89 (90.8) |
| Yes | 9 (9.20) | |
| Lymphatic embolization | No | 85 (86.7) |
| Yes | 13 (13.3) | |
| Adjuvant chemotherapy | No | 52 (53.7) |
| Yes | 46 (46.7) | |
| Adjuvant CT scheme | No chemotherapy treatment | 52 (53.7) |
| FOLFOX | 28 (28.5) | |
| 5 FU + LV | 07 (7.14) | |
| FOLFOX/FOLFIRI + Bevacizumab | 05 (5.10) | |
| FOLFIRI + Cetuximab | 1 (1.02) | |
| XELODA/XELOX | 5 (5.10) |
CT chemotherapy, 5-FU + LV 5-Fluorouracil + Leucovorin (folinic acid), FOLFOX Leucovorin + Oxaliplatin + Oxaliplatin, FOLFIRI Fluorouracil + Leucovorin + Irinotecan, XELODA/XELOX Capecitabine combined with Oxaliplatin